{"podcast":{"title":"Business News Today | 2 Min News | The Daily News Now!","slug":"business-finance-news-today-2-min-news-the-daily-news-now-7726192","podcast_index_feed_id":7726192,"rss_url":"https://feeds.fastcast.ai/the-daily-news-now-business.xml","website_url":"https://thednn.ai/","image_url":"https://image.fastcast.ai/cover/a77b5c94-431e-4490-8653-1f676f1da586.png","author":"The Daily News Now!","episode_count":2000,"summary":"Hosted by Corey with the Story, Business News Today is your daily source for the latest headlines and stories shaping the world of business, finance, and the global economy. From market trends and corporate earnings to startups, entrepreneurship, technology, real estate, consumer trends, and economic policy, we bring you the business news that matters most—in just a few minutes. Whether you're an entrepreneur, investor, executive, business owner, or simply someone who wants to stay informed, Business News Today delivers clear, concise updates to help you understand the forces shaping the economy and the future of business. Business News Today — Business news, all in one place. Powered by AI.","last_synced_at":"2026-09-17T06:21:31.382927+00:00","page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192"},"episode":{"title":"Enliven Therapeutics Stock Move & Outlook","slug":"enliven-therapeutics-stock-move-outlook","published_at":"2026-06-27T16:37:29+00:00","page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/enliven-therapeutics-stock-move-outlook","show_page_url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192","url":"https://api.fastcast.ai/audio/a96d27e9-5f35-457d-a4fe-0bbd95878848.mp3","audio_url":"https://api.fastcast.ai/audio/a96d27e9-5f35-457d-a4fe-0bbd95878848.mp3","summary":"Orbimed Advisors cashed out nearly $39 million by selling 860,000 shares of Enliven Therapeutics, still holding over 6.5 million shares — a move that didn’t hurt the stock, which jumped to $50 after the sale. With a 130% one-year surge, Enliven continues its promising path in cancer drug development, advancing key candidates in early trials for chronic myeloid leukemia and HER2-mutant cancers. Positive clinical data and a strong cash reserve from a recent IPO keep investors optimistic, suggesting Orbimed’s exit may signal confidence in Enliven’s long-term potential. Support the show: Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN: advertise@thednn.ai This is an automated, high-level news summary based on public reporting. Report issues to feedback@thednn.ai. View sources & latest updates: https://sources.thednn.ai/7f6898c447d95db6","meta_description":"Orbimed Advisors cashed out nearly $39 million by selling 860,000 shares of Enliven Therapeutics, still holding over 6.5 million shares — a move that didn…","key_points":[],"chapters":[],"topics":[],"duration_seconds":119,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-finance-news-today-2-min-news-the-daily-news-now-7726192/episodes/enliven-therapeutics-stock-move-outlook/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-finance-news-today-2-min-news-the-daily-news-now-7726192/enliven-therapeutics-stock-move-outlook.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}